Notice for eltrombopag olamine (Novartis Pharmaceuticals Australia Pty Ltd)
Active ingredients
eltrombopag olamine
Date of review outcome
Lapse date
Type
Priority review
Dosage form(s)
Powder for oral suspension & Tablet, film-coated
Indication
Eltrombopag olamine in combination with standard immunosuppressive therapy (IST) for the first-line treatment of patients 2 years and older with severe aplastic anaemia (SAA).
Therapeutic area
Haematology